| Medical and Health Sciences | 2021-2025 | 254 | NL 4 | 99.95 |
| Internal Medicine | Lifetime | 27 | NL 3 | 99.39 |
| Cardiology and Cardiovascular Medicine | Lifetime | 871 | NL 32 | 98.04 |
| Internal Medicine | 2021-2025 | 1 | NL 1 | 99.88 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 260 | NL 15 | 97.84 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 354 | NL 9 | 96.60 |
| Infectious Diseases | 2021-2025 | 973 | NL 24 | 70.24 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 112 | NL 10 | 99.61 |
| COVID-19 Clinical Research Studies | Lifetime | 156 | NL 4 | 99.16 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 176 | NL 15 | 99.47 |
| COVID-19 and healthcare impacts | Lifetime | 103 | NL 1 | 97.89 |
| Long-Term Effects of COVID-19 | Lifetime | 138 | NL 6 | 98.53 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 122 | NL 5 | 99.14 |
| Ultrasound in Clinical Applications | Lifetime | 54 | NL 4 | 98.94 |
| Central Venous Catheters and Hemodialysis | Lifetime | 97 | NL 6 | 99.08 |
| Acute Ischemic Stroke Management | Lifetime | 398 | NL 23 | 98.77 |
| Diagnosis and Treatment of Venous Diseases | Lifetime | 124 | NL 7 | 98.06 |
| Acute Myocardial Infarction Research | Lifetime | 463 | NL 24 | 98.59 |
| Cardiac tumors and thrombi | Lifetime | 617 | NL 18 | 95.06 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 803 | NL 68 | 95.89 |
| Reliability and Agreement in Measurement | Lifetime | 204 | NL 24 | 83.97 |
| Case Reports on Hematomas | Lifetime | 726 | NL 20 | 71.51 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 2 | NL 1 | 99.90 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 41 | NL 3 | 99.47 |
| Ultrasound in Clinical Applications | 2021-2025 | 22 | NL 3 | 97.63 |
| Acute Myocardial Infarction Research | 2021-2025 | 63 | NL 1 | 98.80 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 49 | NL 3 | 98.49 |
| Acute Ischemic Stroke Management | 2021-2025 | 137 | NL 7 | 98.80 |
| COVID-19 and healthcare impacts | 2021-2025 | 173 | NL 3 | 96.36 |
| COVID-19 Clinical Research Studies | 2021-2025 | 866 | NL 18 | 96.44 |
| Cardiac tumors and thrombi | 2021-2025 | 58 | NL 5 | 94.95 |
| Diagnosis and Treatment of Venous Diseases | 2021-2025 | 57 | NL 1 | 95.12 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 127 | NL 6 | 93.62 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 663 | NL 31 | 86.62 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 338 | NL 28 | 82.37 |
| Case Reports on Hematomas | 2021-2025 | 233 | NL 4 | 54.59 |
| Vascular Anomalies and Treatments | 2021-2025 | 652 | NL 15 | 54.24 |
| Reliability and Agreement in Measurement | 2021-2025 | 118 | NL 17 | 45.48 |
